Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [pub- lished correction appears in Lancet. 2009;374:1744]. Lancet. 2003;362: 759 766. 132. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, K ber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Val- sartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [published correction Smith et al AHA/ACCF Secondary Prevention: 2011 Update 2471 appears in N Engl J Med. 2004;350:203]. N Engl J Med. 2003;349: 1893 1906. 133. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P; Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANCEND) Investigators. Effects of angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin- converting enzyme inhibitors: a randomized controlled trial [published correction appears in Lancet. 2008;372:1384]. Lancet. 2008;372: 1174 1183. 134. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547 1559. 135. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Pat- wardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16 29. 136. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. 